|
1
|
Hall IJ, Rim SH, Johnson-Turbes CA,
Vanderpool R and Kamalu NN: The African American Women and Mass
Media campaign: A CDC breast cancer screening project. J Womens
Health (Larchmt). 21:1107–1113. 2012. View Article : Google Scholar
|
|
2
|
Lu J, Steeg PS, Price JE, Krishnamurthy S,
Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, et
al: Breast cancer metastasis: Challenges and opportunities. Cancer
Res. 69:4951–4953. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ursini-Siegel J and Muller WJ: The ShcA
adaptor protein is a critical regulator of breast cancer
progression. Cell Cycle. 7:1936–1943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
6
|
Lytle GH: Immunotherapy of breast cancer:
A review of the development of cell-specific therapy. Semin Surg
Oncol. 7:211–216. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jain S, Thakkar N, Chhatai J, Pal Bhadra M
and Bhadra U: Long non-coding RNA: Functional agent for disease
traits. RNA Biol. 14:522–535. 2017. View Article : Google Scholar :
|
|
9
|
Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST,
Chu LW, Zhang Z, Zhao H, Zheng SL, Isaacs WB, et al: Human
polymorphisms at long non-coding RNAs (lncRNAs) and association
with prostate cancer risk. Carcinogenesis. 32:1655–1659. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao J, Liu Y, Zhang W, Zhou Z, Wu J, Cui
P, Zhang Y and Huang G: Long non-coding RNA Linc00152 is involved
in cell cycle arrest, apoptosis, epithelial to mesenchymal
transition, cell migration and invasion in gastric cancer. Cell
Cycle. 14:3112–3123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen Y, Katsaros D, Loo LW, Hernandez BY,
Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, et al:
Prognostic and predictive values of long non-coding RNA LINC00472
in breast cancer. Oncotarget. 6:8579–8592. 2015.PubMed/NCBI
|
|
12
|
Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H,
Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673
regulated non-small cell lung cancer proliferation, migration,
invasion and epithelial mesenchymal transition by sponging
miR-150-5p. Mol Cancer. 16:118–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Huang C, Gong Z, Zhao Y, Tang K,
Li X, Fan S, Shi L, Li X, Zhang P, et al: Expression of LINC00312,
a long intergenic non-coding RNA, is negatively correlated with
tumor size but positively correlated with lymph node metastasis in
nasopharyngeal carcinoma. J Mol Histol. 44:545–554. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weiss M, Plass C and Gerhauser C: Role of
lncRNAs in prostate cancer development and progression. Biol Chem.
395:1275–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui Y, Yi L, Zhao JZ and Jiang YG: Long
noncoding RNA HOXA11-AS functions as miRNA sponge to promote the
glioma tumorigenesis through targeting miR-140-5p. DNA Cell Biol.
36:822–828. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu XS, Wang F, Li HF, Hu YP, Jiang L,
Zhang F, Li ML, Wang XA, Jin YP, Zhang YJ, et al: LncRNA-PAGBC acts
as a microRNA sponge and promotes gallbladder tumorigenesis. EMBO
Rep. 18:1837–1853. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan Z, Mao W, Bao Y, Zhang M, Su X and Xu
X: The long noncoding RNA CASC9 regulates migration and invasion in
esophageal cancer. Cancer Med. 5:2442–2447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shang C, Sun L, Zhang J, Zhao B, Chen X,
Xu H and Huang B: Silence of cancer susceptibility candidate 9
inhibits gastric cancer and reverses chemoresistance. Oncotarget.
8:15393–15398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y, Hu L, Liang Y, Li J, Wang K, Chen X,
Meng H, Guan X, Yang K and Bai Y: Up-regulation of lncRNA CASC9
promotes esophageal squamous cell carcinoma growth by negatively
regulating PDCD4 expression through EZH2. Mol Cancer. 16:150–162.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su X, Li G and Liu W: The Long Noncoding
RNA Cancer Susceptibility Candidate 9 Promotes Nasopharyngeal
Carcinogenesis via Stabilizing HIF1α. DNA Cell Biol. 36:394–400.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar :
|
|
22
|
Grünhagen J, Bhushan R, Degenkolbe E,
Jäger M, Knaus P, Mundlos S, Robinson PN and Ott CE: MiR-497~195
cluster microRNAs regulate osteoblast differentiation by targeting
BMP signaling. J Bone Miner Res. 30:796–808. 2015. View Article : Google Scholar
|
|
23
|
Sato T, Yamamoto T and Sehara-Fujisawa A:
miR-195/497 induce postnatal quiescence of skeletal muscle stem
cells. Nat Commun. 5:45972014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei W, Zhang WY, Bai JB, Zhang HX, Zhao
YY, Li XY and Zhao SH: The NF-κB-modulated microRNAs miR-195 and
miR-497 inhibit myoblast proliferation by targeting Igf1r, Insr and
cyclin genes. J Cell Sci. 129:39–50. 2016. View Article : Google Scholar
|
|
25
|
Furuta M, Kozaki K, Tanimoto K, Tanaka S,
Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The
tumor-suppressive miR-497-195 cluster targets multiple cell-cycle
regulators in hepatocellular carcinoma. PLoS One. 8:e601552013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
29
|
Shao Y, Ye M, Li Q, Sun W, Ye G, Zhang X,
Yang Y, Xiao B and Guo J: LncRNA-RMRP promotes carcinogenesis by
acting as a miR-206 sponge and is used as a novel biomarker for
gastric cancer. Oncotarget. 7:37812–37824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu X, Mi L, Dong J and Zou J: Long
intergenic non-protein-coding RNA 1567 (LINC01567) acts as a
'sponge' against microRNA-93 in regulating the proliferation and
tumorigenesis of human colon cancer stem cells. BMC Cancer.
17:7162017. View Article : Google Scholar
|
|
31
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepa-tocellular carcinoma. Med Oncol. 31:844–848. 2014.
View Article : Google Scholar
|
|
32
|
Konecny GE: Impact of molecular breast
cancer portraits on new treatment strategies for gynecologic
malignancies. Curr Opin Obstet Gynecol. 25:38–39. 2013. View Article : Google Scholar
|
|
33
|
Kumi-Diaka J, Hassanhi M, Brown J,
Merchant K, Garcia C and Jimenez W: CytoregR inhibits growth and
proliferation of human adenocarcinoma cells via induction of
apoptosis. J Carcinog. 5:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Prasad R, Vaid M and Katiyar SK: Grape
proanthocyanidin inhibit pancreatic cancer cell growth in vitro and
in vivo through induction of apoptosis and by targeting the
PI3K/Akt pathway. PLoS One. 7:e430642012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Atmaca H, Özkan AN and Zora M: Novel
ferrocenyl pyrazoles inhibit breast cancer cell viability via
induction of apoptosis and inhibition of PI3K/Akt and ERK1/2
signaling. Chem Biol Interact. 263:28–35. 2017. View Article : Google Scholar
|
|
36
|
Marrone AK, Beland FA and Pogribny IP:
Noncoding RNA response to xenobiotic exposure: An indicator of
toxicity and carcinogenicity. Expert Opin Drug Metab Toxicol.
10:1409–1422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang S, Ning Q, Zhang G, Sun H, Wang Z and
Li Y: Construction of differential mRNA-lncRNA crosstalk networks
based on ceRNA hypothesis uncover key roles of lncRNAs implicated
in esophageal squamous cell carcinoma. Oncotarget. 7:85728–85740.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Amer M, Elhefnawi M, El-Ahwany E, Awad AF,
Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in
hepa-tocellular carcinoma that increases tumor life span. Tumour
Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y,
Li PY, Wang M, Lin JS and He XX: MiR-497 suppresses angiogenesis
and metastasis of hepatocellular carcinoma by inhibiting VEGFA and
AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu J, Wang T, Cao Z, Huang H, Li J, Liu W,
Liu S, You L, Zhou L, Zhang T, et al: MiR-497 downregulation
contributes to the malignancy of pancreatic cancer and associates
with a poor prognosis. Oncotarget. 5:6983–6993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang S, Mo Y, Midorikawa K, Zhang Z, Huang
G, Ma N, Zhao W, Hiraku Y, Oikawa S and Murata M: The potent tumor
suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal
carcinoma by targeting ANLN and HSPA4L. Oncotarget. 6:35893–35907.
2015.PubMed/NCBI
|
|
42
|
Zhao H and Piwnica-Worms H: ATR-mediated
checkpoint pathways regulate phosphorylation and activation of
human Chk1. Mol Cell Biol. 21:4129–4139. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Q, Guntuku S, Cui XS, Matsuoka S,
Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A,
et al: Chk1 is an essential kinase that is regulated by Atr and
required for the G(2)/M DNA damage checkpoint. Genes Dev.
14:1448–1459. 2000.PubMed/NCBI
|
|
44
|
Schmitt E, Boutros R, Froment C, Monsarrat
B, Ducommun B and Dozier C: CHK1 phosphorylates CDC25B during the
cell cycle in the absence of DNA damage. J Cell Sci. 119:4269–4275.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bryant C, Scriven K and Massey AJ:
Inhibition of the checkpoint kinase Chk1 induces DNA damage and
cell death in human Leukemia and Lymphoma cells. Mol Cancer.
13:147–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Parsels LA, Morgan MA, Tanska DM, Parsels
JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence
TS, et al: Gemcitabine sensitization by checkpoint kinase 1
inhibition correlates with inhibition of a Rad51 DNA damage
response in pancreatic cancer cells. Mol Cancer Ther. 8:45–54.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Grabauskiene S, Bergeron EJ, Chen G,
Thomas DG, Giordano TJ, Beer DG, Morgan MA and Reddy RM: Checkpoint
kinase 1 protein expression indicates sensitization to therapy by
checkpoint kinase 1 inhibition in non-small cell lung cancer. J
Surg Res. 187:6–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Itamochi H, Nishimura M, Oumi N, Kato M,
Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, et al:
Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance
in clear cell carcinoma of the ovary. Int J Gynecol Cancer.
24:61–69. 2014. View Article : Google Scholar
|
|
49
|
Cole KA, Huggins J, Laquaglia M, Hulderman
CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris
G, et al: RNAi screen of the protein kinome identifies checkpoint
kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl
Acad Sci USA. 108:3336–3341. 2011. View Article : Google Scholar : PubMed/NCBI
|
